Carmona-Rocha, E, Rusiñol, L, Puig, L. Erosive Lesions in the Legs of an Elderly Woman. INDIAN JOURNAL OF DERMATOLOGY. 2025; 70(1)DOI:10.4103/ijd.ijd_851_23. PMID:39896302. IF:1.300(Q3/7D).

Dauden, E, Ortiz-Salvador, JM, Notario, J, Puig, L, Santos-Juanes, J, Herrera-Acosta, E, Gomez-Labrador, L, Ruiz-Villaverde, R. Secukinumab for Treatment of Plaque Psoriasis in Real-World Clinical Practice in Spain: A Literature Review. Journal of Clinical Medicine. 2025; 14(2)DOI:10.3390/jcm14020478. PMID:39860484. IF:2.900(Q1/2D).

Hernández, G, Martin, M, Alonso, S, Romero, I, Salvado, N, Farrés, M, Osuna, C, Bustínduy, M, de Araníbar, JG, Manresa, M, Velasco, M, Ferrer, A, Riesco, M, Genao, D, Ruíz-Villaverde, R, Boquete, L, Martínez, C, Rull, E, Descalzo, MA. Measurement Assessment of Minimal Disease Activity In Psoriasis in Spain: A National Cross-Sectional Study. Actas Dermo-Sifiliograficas. 2025; 116(1)DOI:10.1016/j.ad.2024.05.022. PMID:38876209. IF:(Q/D).

Hernández, GC, Martín, MA, Alonso, SA, Romero, IB, Salvado, NE, Farrés, MF, Osuna, CG, Bustínduy, MG, de Aranibar, JGL, Manresa, MJ, Velasco, ML, Ferrer, AL, Riesco, MR, Genao, DR, Ruíz-Villaverde, R, Boquete, LS, Martínez, CS, Rull, EV, Descalzo, MA. Measurement Assessment of Minimal Disease Activity in Psoriasis in Spain: A National Cross-Sectional Study. Actas Dermo-Sifiliograficas. 2025; 116(1)DOI:10.1016/j.ad.2024.10.009. PMID:. IF:(Q/D).

Mateu-Arrom, L, Puig, L. Infection Risk and Vaccination in the Management of Psoriasis: Considerations for Biologic Therapy. Psoriasis-Targets And Therapy. 2025; 15DOI:10.2147/PTT.S510141. PMID:40237012. IF:(Q/D).

Vestergaard, C, Thaci, D, Puig, L, Papp, KA, Gold, LS, Peñas, PF, Huan, YH, Dossenbach, M, Falques, M, Agell, H, Du Jardin, KG. MEAN ABSOLUTE EASI AND PRURITUS ACHIEVED BY LEBRIKIZUMAB OVER 16 WEEKS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS. ACTA DERMATO-VENEREOLOGICA. 2025; 105DOI:. PMID:. IF:3.700(Q1/2D).

Ceravalls, J, Gímenez-Arnau, AM, Expósito-Serrano,, Chico, NF, Moya, AL, Bielsa,, Ribó, P, Mascaro-Hereza, B, Bonfill-Orti, M, Spertino, J, Serra, E, Baliu-Pique, C, Mele-Ninot, G. Predictive Factors and Optimization of Omalizumab in Chronic Spontaneous Urticaria: A Multicenter Study of 257 Patients. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY. 2025; 35(3)DOI:10.18176/jiaci.1053. PMID:39950575. IF:4.800(Q1/1D).

Garg, AX, Marcucci, M, Cuerden, MS, Sontrop, JM, Painter, TW, Lomivorotov, V, Sessler, DI, Chan, MTV, Borges, FK, Leslie, K, Duceppe, E, Parikh, CR, Roshanov, P, Martínez-Zapata, MJ, Wang, CY, Xavier, D, Efremov, S, Landoni, G, Kleinlugtenbelt, YV, Szczeklik, W, Schmartz, D, Meyhoff, CS, Short, TG, Amir, M, Torres, D, Wittmann, M, Patel, A, Ruetzler, K, Parlow, JL, Jayaram, R, Polanczyk, CA, Fleischmann, E, Tandon, V, Astrakov, SV, Conen, D, Wu, WKK, Cheong, CC, Ayad, S, Kirov, M, de Nadal, M, Likhvantsev, VV, Paniagua, P, Aguado, HJ, Ofori, SN, Vincent, J, Copland, I, Balasubramanian, K, Biccard, BM, Srinathan, S, Ismoilov, S, Wang, MK, Kurz, A, Belley-Cote, EP, Bhatt, K, Eikelboom, J, Gross, P, Lamy, A, McGillion, M, McIntyre, W, Richards, T, Spence, J, Van Helder, T, Whitlock, R, Devereaux, PJ. A sub-study of the POISE-3 randomized trial examined effects of a perioperative hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of acute kidney injury. KIDNEY INTERNATIONAL. 2025; 107(1)DOI:10.1016/j.kint.2024.10.007. PMID:39490985. IF:12.600(Q1/1D).